Alex Thurman Sells 10,000 Shares of Glaukos (NYSE:GKOS) Stock

Glaukos Corporation (NYSE:GKOS) CFO Alex Thurman sold 10,000 shares of the company’s stock in a transaction dated Monday, July 6th. The shares were sold at an average price of $150.00, for a total transaction of $1,500,000.00. Following the transaction, the chief financial officer owned 43,681 shares in the company, valued at approximately $6,552,150. The trade was a 18.63% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Glaukos Trading Up 1.5%

Shares of NYSE:GKOS traded up $2.24 during trading on Wednesday, hitting $152.89. 1,058,781 shares of the company’s stock were exchanged, compared to its average volume of 851,252. Glaukos Corporation has a 1-year low of $73.16 and a 1-year high of $154.61. The firm has a 50-day moving average price of $131.05 and a two-hundred day moving average price of $120.19. The company has a current ratio of 5.43, a quick ratio of 4.73 and a debt-to-equity ratio of 0.10. The firm has a market cap of $8.98 billion, a P/E ratio of -46.61 and a beta of 0.75.

Glaukos (NYSE:GKOS) last announced its quarterly earnings data on Wednesday, April 29th. The medical instruments supplier reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($0.30) by $0.12. Glaukos had a negative net margin of 34.34% and a negative return on equity of 6.92%. The business had revenue of $150.57 million for the quarter, compared to analyst estimates of $137.00 million. During the same period in the prior year, the business posted ($0.22) earnings per share. Glaukos’s revenue was up 41.2% compared to the same quarter last year. Equities analysts predict that Glaukos Corporation will post -0.57 earnings per share for the current year.

Hedge Funds Weigh In On Glaukos

A number of large investors have recently added to or reduced their stakes in GKOS. First Horizon Corp boosted its stake in shares of Glaukos by 1,715.4% during the 4th quarter. First Horizon Corp now owns 236 shares of the medical instruments supplier’s stock worth $27,000 after acquiring an additional 223 shares during the period. Los Angeles Capital Management LLC bought a new stake in Glaukos in the 4th quarter valued at $28,000. Larson Financial Group LLC lifted its holdings in Glaukos by 62.0% during the 4th quarter. Larson Financial Group LLC now owns 345 shares of the medical instruments supplier’s stock valued at $39,000 after purchasing an additional 132 shares during the last quarter. Parallel Advisors LLC lifted its holdings in Glaukos by 159.2% during the 1st quarter. Parallel Advisors LLC now owns 368 shares of the medical instruments supplier’s stock valued at $40,000 after purchasing an additional 226 shares during the last quarter. Finally, Farther Finance Advisors LLC boosted its position in Glaukos by 111.4% during the fourth quarter. Farther Finance Advisors LLC now owns 408 shares of the medical instruments supplier’s stock worth $46,000 after purchasing an additional 215 shares during the period. Institutional investors own 99.04% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the company. HC Wainwright initiated coverage on Glaukos in a research report on Monday. They issued a “buy” rating and a $168.00 price target on the stock. Wells Fargo & Company upped their price objective on Glaukos from $135.00 to $138.00 and gave the company an “overweight” rating in a report on Thursday, April 30th. Piper Sandler restated an “overweight” rating and set a $165.00 target price on shares of Glaukos in a report on Wednesday, July 1st. JPMorgan Chase & Co. boosted their target price on Glaukos from $120.00 to $140.00 and gave the stock an “overweight” rating in a research report on Thursday, April 30th. Finally, William Blair reaffirmed an “outperform” rating on shares of Glaukos in a research note on Tuesday, May 26th. Thirteen investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $151.62.

Glaukos Company Profile

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.